Navigation Links
Real-Time Quantification of Genomic DNA Using DyNAzyme II DNA Polymerase and SYBR Green I Dye

Mimi Amutan and David Batey, Ph.D.


Abstract
Real-time quantification was performed for lambda and human genomic DNA on the DNA Engine Opticon system (MJ Research). DyNAzyme II DNA polymerase* was used for amplification, and SYBR Green I fluorescent dye was used for detection. The sensitivity and linear dynamic range of the assay was tested for ranges of 100 to 1x108 initial copies of lambda DNA and 75 to 7.5x104 initial copies of human DNA. Precision of the assay was measured with lambda template and standard deviations of 0.3 cycles or less were obtained for quadruplicate samples. This assay has been shown to be both reliable and precise for the quantification of genomic DNA templates.


Introduction
Quantification of DNA and RNA from biological samples can be effectively accomplished using real-time amplification methods1. The predominant chemistries are based on either the binding of fluorescent dyes to the double stranded structure of DNA or the hybridization of specific probes, such as TaqMan probes2 and molecular beacons3. The simplicity and directness of using binding dyes such as SYBRGreen I (SGI) make this a desirable alternative for many applications4.

SGI is a dsDNA binding dye that has proven exceptionally useful for assays requiring sensitive nucleic acid detection. The fluorescence of SGI is enhanced approximately 1000-fold upon binding dsDNA5, making it ideal for detection of amplification products. Because SGI binds to all dsDNA, it does not have to be customized for individual templates. Detection formats utilizing hybridization probes require careful design of template-specific primer sets. SYBR Green I assays require only the two primers needed for amplificationneither of them labeled.

DyNAzyme II DNA polymerase provides superior results in a wide variety of PCR applications. This polymerase, isolated from Thermus brockianus, demonstrates better thermal stability than Taq DNA polymerase, and the ability to maintain optimal activity over a broad range of reaction conditions. DyNAzyme II is also inherently more resistant than Taq to the inhibitory effects of SGI. In this study, we present real-time quantitative PCR results indicating the sensitivity and precision of assays incorporating DyNAzyme II DNA polymerase and SGI for quantitation of starting copy number using both lambda and human genomic DNA templates.


Methods
DyNAzyme II DNA polymerase was from Finnzymes (F-503L). SGI and lambda DNA were from Molecular Probes (S-7567, P-7589); human genomic DNA was from Sigma (D-3160). Reaction components were assembled in low-profile microplates (MJ Research

MLL-9651) or strip tubes (MJ Research TLS-0851) and sealed with ultra-clear strip caps (MJ Research TCS-0803). Volumes of individual components and final reaction concentrations are listed in Table 1.

SGI reagents are typically obtained at high concentrations (e.g., 10,000X). We define a 10X SGI solution as one giving 0.40.01 O.D. when measured at 495nm. SGI was diluted to a 10X working stock with 0.1X TE buffer.

The following primer set was used in PCR reactions with lambda DNA to generate a 100bp amplicon. The sequences for the primers were: forward primer, 5-GCA-AGT-ATC-GTT-TCC-ACC-GT-3, and reverse primer, 5-TTA-TAA-GTC-TAA-TGA-AGA-CAA-ATC-CC-3

The -actin primers used for amplification of human genomic DNA generate a 294bp amplicon. Sequences were: forward, 5-TCA-CCCACA- CTG-TGC-CCA-TCT-ACG-A-3, and reverse, 5-CAG-CGGAAC- CGC-TCA-TTG-CCA-ATG-G-3

Following reaction assembly, the plates or tubes were transferred to the DNA Engine Opticon real-time system, where cycling was performed according to the program listed in Table 2.

The cycle threshold C(t) line was set using the signal/noise ratio option in the Opticon Monitor software (MJ Research) set to 10 standard deviations above the mean fluorescence values for the first 37 cycles. This threshold is automatically applied to all wells and allows the comparison of standards and samples at a point that provides the most consistent results. It is critical that within any experiment, C(t) values for both standards and samples be determined using the same threshold level.

A concentration series of lambda DNA was prepared from a 0.5g/l stock. 1l of each dilution in 20l reactions was used to generate the standard curve. The standard curve for the human genomic sequence was prepared using genomic DNA from human placenta. Serial dilutions were made and analyzed to generate the standard curve.


Results
Lambda DNA Template: Linear Range and Reproducibility
Plotting fluorescence signal vs. cycle number (Figure 1a) indicates that the concentration of dsDNA in each sample rose above background fluorescence levels, and then entered a stage of exponential amplification. The C(t) values, the cycle at which the measured fluorescence intersects the cycle threshold line, decrease proportionally with the increase in initial DNA concentration. This trend is expected since higher amounts of initial template more quickly generate the amount of product necessary to be detected with SGI. The linear range extends from 108 to 102 copies of lambda DNA initially present in the reaction. A plot of log quantity vs. C(t) cycle for the 100bp amplicon is shown in Figure 1b. The regression coefficient is 0.991, indicating a strong linear correlation.

The precision of this assay was measured by calculating the variation in C(t) values across the four replicates at each template concentration. The standard deviation for C(t) values was found to be 0.3 units or less as shown in Table 3.

Figure 2 shows the melting curves for the four replicate lambda DNA standards containing 104 copies per reaction. The curve shows the typical smooth decline in fluorescence with an increase in temperature as the strands of dsDNA dissociate and bound SGI is released. The negative first derivative calculation is also shown. Here, the point of inflection for the curve, the melting point (Tm), is clearly seen as a single, common peak at approximately 82C. This peak corresponds to the predicted melting temperature of the amplicon, indicating amplification of the amplicon of interest. Anomalies due to contamination, primer-dimer, false priming, etc., are not evident in the negative first derivative plot, as indicated by the lack of additional peaks or of abnormal broadening of the single peak.

Human Genomic DNA Template: Patient Samples Quantified Using a Standard Curve
A standard curve generated from human genomic DNA is shown in Figure 3. A linear curve in the range of 7.5x104 copies/reaction to 75 copies/reaction with r2=0.993 was obtained. Two samples of human genomic DNA were also tested. By interpolation of the standard curve, the first patient sample was determined to have an initial concentration of 254 copies/l, the second had 357 copies/l.

Specificity of the PCR was measured in two ways. First, melting curve analysis was performed on each sample. For example, the melting curve analysis for patient sample 1 revealed a single peak at 88.5C, which indicates exclusive amplification of the -actin amplicon as seen in Figure 4. Second, gel electrophoresis was performed to analyze the PCR products. Figure 5 reveals single bands for each standard and sample, indicating specific amplification of the desired product with only minor amplification of a primer-dimer.


Discussion
Broad Dynamic Range for Lambda and Human DNA
DyNAzyme II DNA polymerase can be used successfully with SYBR Green I dye to quantify DNA from small genomes as well as the more complex human genome. Experiments revealed a linear relationship between log starting copy number and C(t) value over at least 6 orders of magnitude for the lambda genomic DNA template, and over at least 3 orders of magnitude for the human genomic DNA template. The broad dynamic range of starting template that can be detected makes this assay particularly valuable when sample DNA concentrations are unknown or vary widely.

In this study, the lower limit of the standard range was 100 copies of lambda DNA, or 75 copies of human genomic DNA per reaction. Other studies have shown linear results below this level. Though not necessary in this application, detection down to several copies of template could be valuable when analyzing small populations of cells or trace amounts of DNA.

Protocol Adaptable for a Wide Variety of Applications
The protocol presented here can be applied to a wide variety of PCR applications by following several guidelines to modify the protocol for work with SYBR Green I. Because SYBR Green I stabilizes dsDNA, the denaturing temperature of the cycling protocol should be raised approximately 2C in order to ensure complete denaturation of the duplex. In addition, it is recommended that the annealing temperature of PCR primers be optimized for the SGI reaction conditions. This is accomplished by running test reactions with an annealing temperature gradient. The temperature gradient can be programmed into the cycling protocol through the Opticon Monitor software. Melting curves and agarose gel data can be used to evaluate yield and specificity for the target amplicon.

DMSO for the Most Challenging Templates
A wide variety of samples can be analyzed with the protocol described here. The human genomic DNA amplified with -actin primers represents an optimal sample in terms of purity and ease of amplification. However, amplification of challenging templates may benefit from modification of reaction conditions, such as the addition of DMSO. The destabilizing effect of DMSO on double-stranded DNA reduces the denaturation temperature of the amplicon thereby facilitating the amplification of templates with strong secondary structure. Success has been experienced with the addition of DMSO in concentrations of up to 5% (vol/vol). Caution must be used when adding DMSO to reactions, as the destabilizing effect on dsDNA will result in a decrease of bound SGI, and reduction of the fluorescence signal. Addition of DMSO will also lower the Tm for both the primers and the amplicon. Incremental addition of DMSO is recommended.

Selection of Read Temperatures Enhances Specificity
Melting curve analysis indicates this protocol can be used for analysis of amplified template without complications from side reactions, such as primer-dimer formation. To avoid primer-dimer interference with C(t) value determination, the temperature at which the fluorescence was read during each cycle was adjusted to 78C, a temperature above the melting point of the primer-dimers. At this temperature, the double stranded primer-dimers should be denatured, releasing bound SGI and diminishing their contribution to the fluorescence signal. At this same temperature, the longer PCR product remains annealed, and is directly correlated to the fluorescence detected. Typically, the read temperature is set three degrees below the Tm of the amplicon. Melting temperatures for both the primer-dimers and the PCR product are determined by analyzing melting curve data.

The results discussed here highlight DyNAzyme II as a robust polymerase that can be used with SYBR Green I dye in real-time PCR applications. The protocol listed here can be used to provide accurate, reproducible quantitation data for both lambda and human genomic DNA templates over a broad concentration range. The discussion of read temperatures, as well as the guidelines for DMSO use and denaturing and annealing temperatures, provides the user with some basic tools for optimizing real-time fluorescence detection of amplification reactions using SYBR Green I.


References
1. Bustin, S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. Journal of Mol Endocrinology 25:169-193 (2000).

2. Gibson, U.E., Heid, C.A. and Williams, P.M. A novel method for real time quantitative RT-PCR. Genome Research 6:995-1001 (1996).

3. Tyagi, S. and Kramer, F.R. Molecular beacons: probes that fluoresce upon hybridization. Nature Biotechnology 14:303-8 (1996).

4. Morrison, T.B., Weis, J.J. and Wittwer, C.T. Quantification of low-copy transcripts by continuous SYBR Green I monitoring during amplification. Biotechniques 24:954-9 (1998).

5. Cosa, G., Focsaneanu, K.S., McLean, J.R., McNamee, J.P., and Scaiano, J.C. Photophysical properties of fluorescent DNA-dyes bound to single- and double-stranded DNA in aqueous buffered solution. Photochem Photobiol 73: 585-599 (2001).

6. For more information, please refer to www.finnzymes.fi

*This product is sold under licensing agreements with F. Hoffmann-LaRoche Ltd., Roche Molecular Systems, Inc. and the Applied Biosystems Group of Applera Corporation. The purchase of this product is accompanied by a limited license to use it in the Polymerase Chain Reaction (PCR) process in conjunction with a thermal cycler whose use in the automated performance of the PCR process is covered by the up-front licensing fee, either by payment to Applied Biosystems or as purchased, i.e., an authorized thermal cycler.


back to top
'"/>

Source:


Page: All 1 2 3 4 5 6 7 8

Related biology technology :

1. Detection of Genetically Modified Soybean in Processed Foods Using Real-Time Quantitative PCR with SYBR Green I Dye on the DNA Engine Opticon 2 System
2. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
3. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
4. Real-Time Multiplex PCR from Genomic DNA Using the iCycler iQ Detection System
5. Quantitative Analysis of Protein-DNA Associations in Vivo Using Real-Time PCR, Rev A
6. Quantitation of Lymphangiogenesis Using the iCycler iQ Real-Time PCR Detection System and Scorpions Detection System, Rev A
7. Rapid, Reproducible Real-Time Quantitative RT-PCR Using the iCycler iQ Real-Time PCR Detection System and iQ Supermix, Rev A
8. Real-Time Immuno-PCR on the iCycler iQ System, Rev A
9. Real-Time PCR/Melt-Curve Analysis: SNP Detection With FRET, Rev A
10. Real-Time PCR: General Considerations, Rev A
11. Quantification made easy
Post Your Comments:
(Date:7/11/2014)... , July 11, 2014  Researchers have ... three-dimensional images. The new technology, called Virtual Finger, ... small structures like neurons and synapses using the ... unique technology makes 3D imaging studies orders of ... at an unprecedented level across many areas of ...
(Date:7/10/2014)... Product and process impurities in biopharmaceuticals ... are often “lost in the noise,” making their ... Dr. Rowel Tobias, Senior Scientist, Protein Chemistry at ... Quality at Nanotherapeutics, Inc., to lear about a ... and quantitation while achieving the required specificity and ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Terascala, the ... announced that Alan Swahn, a former vice president of ... team as vice president of marketing. Terascala’s software when ... and NetApp create the highest performance and most reliable ... appointed to guide Terascala’s channel expansion and broaden its ...
(Date:7/10/2014)... 10, 2014 OMICS Group’s 5th International ... 18-20 August, 2014 at Double Tree by Hilton Beijing, ... developments in Analytical & Bioanalytical research methods only to ... on this occasion, Dr. Srinubabu Gedela, MD of OMICS ... is a remarkable one in bringing a unique and ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4
... Nutriments, the makers of Apocaps®, the world,s first dietary ... federal grant to research the application of its apoptosis-inducing ... part of the U.S. government,s $1 Billion Qualifying Therapeutic ... the U.S. Department of Health and Human Services. The ...
... THIRD QUARTER ENDED SEPTEMBER 30, 2010 ... ... lpUnit=,PRN,; --> ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. for (var ...
... ... ... var shortURL = ""; BitlyCB.alertResponse = function(data) ... first one. for (var r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { ...
Cached Biology Technology:Functional Nutriments Awarded Federal Grant to Apply Its Dog Nutraceutical Research to Human Cancer 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 2ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 3ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 4ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 5ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 6ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 7ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 8ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 9ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 10ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 11ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 12ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 13ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 14ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 15ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 16ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 17ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 18ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 19ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 20ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 21ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 22ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 23ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 24ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 25ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 26ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 27ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 28ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 29ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 30ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 31ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 32ANGIOTECH PHARMACEUTICALS, INC. ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2010 33Oncothyreon Reports Third Quarter 2010 Financial Results 2Oncothyreon Reports Third Quarter 2010 Financial Results 3
(Date:7/11/2014)... There is evidence that under the normal ... and development, maintain neuronal environment, and exhibit ... and neurodegenerative disease. Previous studies have found ... cells after chemical induction have reduced viability, ... application. Prof. Xiaodong Yuan, Kailuan General Hospital, ...
(Date:7/11/2014)... Rio de Janeiro, Brazil- In the brains of ... mechanism that allows an electric or chemical signal ... another. Chemical synapses, which are the most abundant ... inhibitory. Synapse formation is crucial for learning, memory, ... and inhibitory synapses critical for brain function. ...
(Date:7/10/2014)... , June 30, 2014  Aware, Inc. (NASDAQ: ... and services, previously announced on June 26, 2014 that ... dividend of $1.75 per share, or approximately $40 million ... July 10, 2014 and a payment date of July ... that it had set an ex-dividend date for this ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2NASDAQ Sets Ex-Dividend Date for Aware, Inc.'s Special Cash Dividend of $1.75 Per Share 2
... ... survey conducted by WCS scientists, supported by the U.S. Agency for ... gray wolves, markhor goats, and leopard cats are surviving in parts ... camera-trap surveys, transect surveys, and DNA identification of scat samples in ...
... disorder that disrupts memory, thought and behavior, is devastating ... Alzheimer,s Association, one in eight Americans over the age ... University has discovered that an everyday spice in your ... An extract found in cinnamon bark, called ...
... Two of the world,s leading research universities have ... research and create a framework for a biofuels ... of Queensland, Australia, jointly will pursue means of ... and commercialization, and further development and commercialization in ...
Cached Biology News:Wildlife surviving conflict in Afghanistan 2Wildlife surviving conflict in Afghanistan 3Alzheimer's prevention in your pantry 2Clemson University and the University of Queensland form biofuels research partnership 2Clemson University and the University of Queensland form biofuels research partnership 3
EDTA, disodium salt, 1 kg. Ethylene diaminetetraacetic acid.Dihydrate. Assay: 99.0-101.0%, nuclease-free.Risks: 36, 37, 38 ; Safety Precautions: 22, 36, 37. Category: Nucleotides & Enzymes & Biochemi...
Mycoplasma tested...
Alkaline Phosphatase Stabilizer Solution, 1 L...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
Biology Products: